AprilBio Co.,Ltd.

397030· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩18,060+0.33%

2026-09-18

Financials

Valuation Metrics

AprilBio Co.,Ltd.'s Market Cap is ₩4977B. At end of 2025 it was ₩1.5T. Ranked #469 of 2,421 in KR market (top 19%), #168 of 1,640 on KOSDAQ (top 10%), #50 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 22%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	497.71B KRW	KR#469/2,421 Sec#50/231
Revenue	725.4M KRW	KR#2,388/2,421 Sec#220/231
Net Income	-9.01B KRW	KR—/2,421 Sec—/231
Total Assets	97.12B KRW	KR#1,809/2,421 Sec#142/231
Net Assets	96.32B KRW	KR#1,446/2,421 Sec#116/231
Employees	26	KR#2,219/2,421 Sec#207/231
Value
P/B	5.17x	KR#2,252/2,421 Sec#193/231
P/S	686.17x	KR#2,409/2,421 Sec#224/231
Profitability
ROE	-9.36%	KR#1,925/2,421 Sec#144/231
ROA	-9.28%	KR#2,084/2,421 Sec#155/231
Op. Margin	-1324.10%	KR#2,383/2,421 Sec#215/231
Revenue Growth	-91.92%	KR#2,327/2,421 Sec#210/231
Earnings Growth	-1039.37%	KR#1,325/2,421 Sec#93/231
Financial Health
Debt Ratio	0.83%	KR#2/2,421 Sec#1/231
Total Debt	0 KRW	KR—/2,421 Sec—/231
Cash	7.07B KRW	KR#1,873/2,421 Sec#165/231
Performance
1Y Return	-35.15%	KR#1,710/2,421 Sec#139/231
1M Return	-31.33%	KR#2,359/2,421 Sec#223/231
From 52W High	-76.45%	KR#2,311/2,421 Sec#207/231
1Y MDD	-77.12%	KR#2,243/2,421 Sec#199/231
Trading
Volume	157,717 shares	KR#569/2,421 Sec#40/231
Trading Value	2.85B KRW	KR#474/2,421 Sec#45/231
Foreign Own.	10.14%	KR#472/2,421 Sec#40/231
Per Share
EPS	-327 KRW	KR—/2,421 Sec—/231
BPS	3,495 KRW	KR#1,756/2,421 Sec#129/231

Company Info

CEO 차상훈

Employees 26

Founded 2013

HQ 강원도 춘천시, KR

Website www.aprilbio.com/

동사는 2013년 교원창업 형태로 설립된 연구개발 중심 기업임. HuDVFab library와 SAFA 플랫폼을 보유하고, 이를 기반으로 항체치료제, 이중항체, 지속형 재조합 단백질 의약품 등을 개발하고 있음. 자가면역질환, 염증질환, 암, 희귀질환을 목표로 신약 후보물질을 발굴하고 글로벌 기술이전을 통해 수익을 창출하는 RIPCO 모델을 운영하며, 장기적으로 FIPCO 모델로의 전환을 계획하고 있음. 에이프릴바이오는 2013년에 설립되었으며 강원도 춘천시에 본사를 두고 있습니다.